BS
BMS (New York, NY). 2024 revenue ~$48B. Oncology: Opdivo, Eliquis, Revlimid. Celgene acquisition (2019). API synthesis in Syracuse, NY and Swords, Ireland. CAR-T cell therapy: Breyanzi, Abecma.
BS
Bristol-Myers Squibb
@bms
Joined July 2026
4 Following9 Followers